Organism Function
Senate Fails to Pass Bill Codifying Access to Contraception Amid Republican Opposition
Contraception, Senate Vote, Republican Opposition, Reproductive Rights, Birth Control
Repare Backer Amplitude Ventures Launches $192M Biotech Fund for Development and Growth
Amplitude Ventures, biotech fund, Repare Therapeutics, development, growth, investment, biotechnology
Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease
** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment
J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks
J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.
BIO Undergoes Transformative Restructuring for Future Growth
BIO, lobbying group, reorganization, restructuring, layoffs, future growth, transformation, biotechnology industry.
EMA Recommends Halt on Preterm Birth Medications Due to Safety Concerns
European Medicines Agency (EMA), safety committee, preterm birth drugs, suspension, safety concerns, pregnancy, fetal development.
MacroGenics Reviews Safety Protocols Following Three Patient Deaths in Prostate Cancer Drug Trial
MacroGenics, Phase 2 trial, prostate cancer, patient deaths, safety review, margetuximab, bispecific antibody
Takeda Pharmaceuticals Revises Profit Forecast Due to Vyvanse Patent Expiration, Plans $900M Restructuring by 2024
Takeda Pharmaceuticals, Vyvanse, patent expiration, profit outlook, restructuring, ADHD medication
Endo’s Par Pharmaceutical Recalls Blood Pressure Medication Due to Potential Contamination
Endo, Par Pharmaceutical, recall, blood pressure medication, contamination, quinapril HCl/ hydrochlorothiazide tablets, USP 20 mg/12.5 mg, lot number 0KG190092, expiration date 03/2022
Biogen’s Leqembi Gains Momentum: A Steady Pace in Market Growth
Biogen, Leqembi, Alzheimer’s disease, clinical trials, FDA approval, market growth, steady pace, neurology, healthcare, pharmaceuticals.